Health ❯ Healthcare ❯ Regulatory Affairs ❯ Drug Approval

Clinical Guidelines

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

NEJM publication with ESMO presentation positions the regimen for stronger guidelines, with manageable safety tradeoffs.

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer